AbCellera Biologics Inc. - Common Shares (ABCL) earnings
ABCL earnings moved a median of -1.60% by the close. Quarterly and annual ABCL reports and results, each read against the price at its own news timestamp. Back to the ABCL overview →
22 measured ABCL earnings events.
Where these ABCL earnings landedvs 22 measured ABCL earnings reactions
| Middle 50% of ABCL earnings reactions | -4.32% to +2.83% |
|---|---|
| Median reaction (to close) | -1.60% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 ABCL earnings events with a measured close landed between -4.32% and +2.83%; 41% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 | Press release | +1.79% | -1.86% | |
| Form 10-Q AbCellera Biologics Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.10% | +12.78% | |
| As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22 | Press release | -0.58% | -1.75% | |
| AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 | Press release | +3.10% | -4.18% | |
| Form 10-Q AbCellera Biologics Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.84% | +3.99% | |
| AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call | Press release | +0.00% | -2.74% | |
| AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 | Press release | +0.58% | +2.62% | |
| Form 10-K AbCellera Biologics Inc. For: Dec 31 | SEC filing · Form 10-K | -4.17% | -5.06% | |
| Form 10-Q AbCellera Biologics Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.95% | +2.90% | |
| AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | +0.62% | +3.29% | |
| Form 10-Q AbCellera Biologics Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.10% | -11.46% | |
| AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 | Press release | -1.11% | -3.95% | |
| Form 10-Q AbCellera Biologics Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.48% | -1.46% | |
| AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 | Press release | -0.49% | +3.46% | |
| Form 10-K AbCellera Biologics Inc. For: Dec 31 | SEC filing · Form 10-K | -6.43% | -4.96% | |
| Form 10-Q AbCellera Biologics Inc. For: Sep 30 | SEC filing · Form 10-Q | +3.20% | +8.80% | |
| AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 | Press release | +0.77% | +0.39% | |
| Form 10-Q AbCellera Biologics Inc. For: Jun 30 | SEC filing · Form 10-Q | -5.09% | -4.36% | |
| AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 | Press release | +0.55% | +1.46% | |
| Form 10-Q AbCellera Biologics Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.97% | -4.95% | |
| AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 | Press release | +0.45% | -0.23% | |
| Form 10-K AbCellera Biologics Inc. For: Dec 31 | SEC filing · Form 10-K | -8.02% | -8.38% |
Keep exploring
More ABCL: analyst actions → · SEC filings → · ABCL overview →